Recombinant human glucagon - Adocia

Drug Profile

Recombinant human glucagon - Adocia

Alternative Names: BC Glucagon; Biochaperone® Glucagon

Latest Information Update: 21 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adocia
  • Class Antihypoglycaemics; Pancreatic hormones
  • Mechanism of Action Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Hypoglycaemia

Most Recent Events

  • 20 Nov 2017 Efficacy and adverse events data from a phase I trial in Hypoglycaemia released by Adocia
  • 04 Sep 2017 Adocia completes a phase I trial in Hypoglycaemia in Germany (SC) (NCT03176524)
  • 22 Jun 2017 Recombinant human glucagon - Adocia is available for licensing as of 22 Jun 2017. http://www.adocia.fr/WP/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top